SAFETY DATA SHEET

Mometasone / Clotrimazole / Gentamicin Formulation

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Mometasone / Clotrimazole / Gentamicin Formulation

Manufacturer or supplier's details
Company : MSD
Address : 91-105 Harpin Street
          Bendigo  3550, Victoria Austrailia
Telephone : +1-908-740-4000
Emergency telephone number : 1 800 033 461
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use : Veterinary product

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification
Reproductive toxicity : Category 1A

GHS label elements
Hazard pictograms : ⚠
Signal word : Danger
Hazard statements : H360D May damage the unborn child.
Precautionary statements : Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read
     and understood.
P281 Use personal protective equipment as required.
Response:
P308 + P313 IF exposed or concerned: Get medical advice/
     attention.
Storage:
P405 Store locked up.
Disposal:
P501 Dispose of contents/ container to an approved waste
     disposal plant.
SAFETY DATA SHEET

Mometasone / Clotrimazole / Gentamicin Formulation

Other hazards which do not result in classification
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>White mineral oil (petroleum)</td>
<td>8042-47-5</td>
<td>&gt; 90 -&lt;= 100</td>
</tr>
<tr>
<td>clotrimazole</td>
<td>23593-75-1</td>
<td>1</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>1403-66-3</td>
<td>0.5</td>
</tr>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
<td>0.1</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed:
May damage the unborn child.

Protection of first-aiders : First Aid responders should pay attention to self-protection,
and use the recommended personal protective equipment
when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-
Exposure to combustion products may be a hazard to health.
SAFETY DATA SHEET

Mometasone / Clotrimazole / Gentamicin Formulation

Version 3.8
Revision Date: 10.10.2020
SDS Number: 412809-00015
Date of last issue: 23.03.2020
Date of first issue: 14.12.2015

fighting
Hazardous combustion products: Carbon oxides

Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

Special protective equipment for firefighters:
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

Hazchem Code: •3Z

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
- Use personal protective equipment.
- Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions:
- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Prevent spreading over a wide area (e.g. by containment or oil barriers).
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
- Soak up with inert absorbent material.
- For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
- Clean up remaining materials from spill with suitable absorbent.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures:
- See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation:
- If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling:
- Do not get on skin or clothing.
- Do not breathe mist or vapours.
- Do not swallow.
- Avoid contact with eyes.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-
Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types:
Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>White mineral oil (petroleum)</td>
<td>8042-47-5</td>
<td>TWA (Mist)</td>
<td>5 mg/m3</td>
<td>AU OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Inhalable particulate matter)</td>
<td>5 mg/m3</td>
<td>ACGIH</td>
</tr>
<tr>
<td>clotrimazole</td>
<td>23593-75-1</td>
<td>TWA</td>
<td>0.2 mg/m3 (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>1403-66-3</td>
<td>TWA</td>
<td>0.1 mg/m3 (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
<td>TWA</td>
<td>1 µg/m3 (OEB 4)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Further information: Skin</td>
<td>Wipe limit 10 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures: All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies. If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment
Respiratory protection: If adequate local exhaust ventilation is not available or expo-
Filter type: Combined particulates and organic vapour type

Hand protection: Chemical-resistant gloves

Remarks: Consider double gloving.

Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: suspension

Colour: white to off-white

Odour: oily

Odour Threshold: No data available

pH: No data available

Melting point/freezing point: No data available

Initial boiling point and boiling range: No data available

Flash point: No data available

Evaporation rate: No data available

Flammability (solid, gas): Not applicable

Flammability (liquids): No data available

Upper explosion limit / Upper flammability limit: No data available

Lower explosion limit / Lower flammability limit: No data available

Vapour pressure: No data available
SAFETY DATA SHEET

Mometasone / Clotrimazole / Gentamicin Formulation

Relative vapour density : No data available
Relative density : No data available
Density : No data available
Solubility(ies)
  Water solubility : No data available
Partition coefficient: n-octanol/water : Not applicable
Auto-ignition temperature : No data available
Decomposition temperature : No data available
Viscosity
  Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Particle size : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous rea-
thons : Can react with strong oxidizing agents.
Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation
  Skin contact
  Ingestion
  Eye contact

Acute toxicity
Not classified based on available information.

Product:
  Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
                      Method: Calculation method
  Acute dermal toxicity : Acute toxicity estimate: > 2,000 mg/kg
                          Method: Calculation method
Components:

White mineral oil (petroleum):
- Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
- Acute inhalation toxicity: LC50 (Rat): > 5 mg/l
  Exposure time: 4 h
  Test atmosphere: dust/mist
  Assessment: The substance or mixture has no acute inhalation toxicity
- Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg
  Assessment: The substance or mixture has no acute dermal toxicity

clotrimazole:
- Acute oral toxicity: LD50 (Rat): 708 mg/kg
  LD50 (Mouse): 761 mg/kg
  LD50 (Rabbit): > 1,000 mg/kg
- Acute inhalation toxicity: LC50 (Rat): > 0.73 mg/l
  Exposure time: 4 h
  Test atmosphere: dust/mist
- Acute dermal toxicity: LD50 (Mouse): 923 mg/kg

Gentamicin:
- Acute oral toxicity: LD50 (Rat): 8,000 - 10,000 mg/kg
  LD50 (Mouse): 10,000 mg/kg
- Acute inhalation toxicity: LC50 (Rat): > 0.2 mg/l
  Exposure time: 4 h
  Test atmosphere: dust/mist
  Remarks: No mortality observed at this dose.
- Acute toxicity (other routes of administration):
  LD50 (Rat): 67 - 96 mg/kg
  Application Route: Intravenous
  LD50 (Rat): 371 - 384 mg/kg
  Application Route: Intramuscular
  LDLo (Monkey): 30 mg/kg
  Application Route: Intravenous

Mometasone:
- Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg
  LD50 (Mouse): > 2,000 mg/kg
Acute inhalation toxicity: LC50 (Rat): > 3.3 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3.2 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute toxicity (other routes of administration): LD50 (Rat): 300 mg/kg
Application Route: Subcutaneous
Symptoms: Breathing difficulties

Skin corrosion/irritation
Not classified based on available information.

Components:

White mineral oil (petroleum):
Species: Rabbit
Result: No skin irritation

Clotrimazole:
Species: Rabbit
Result: No skin irritation

Gentamicin:
Species: Rabbit
Result: Mild skin irritation

Mometasone:
Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

White mineral oil (petroleum):
Species: Rabbit
Result: No eye irritation

Clotrimazole:
Species: Rabbit
Result: Mild eye irritation
Gentamicin:
Species: Rabbit
Result: Mild eye irritation

Mometasone:
Species: Rabbit
Result: No eye irritation

Respiratory or skin sensitisation
Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:
White mineral oil (petroleum):
Test Type: Buehler Test
Exposure routes: Skin contact
Species: Guinea pig
Result: negative

Gentamicin:
Remarks: No data available

Mometasone:
Test Type: Maximisation Test
Exposure routes: Dermal
Species: Guinea pig
Assessment: Does not cause skin sensitisation.
Result: negative
Remarks: The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.

Chronic toxicity
Germ cell mutagenicity
Not classified based on available information.

Components:
White mineral oil (petroleum):
Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Method: OECD Test Guideline 474
Result: negative
Remarks: Based on data from similar materials

**clotrimazole:**

**Genotoxicity in vitro:**
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative

- Test Type: Chromosome aberration test in vitro
  Result: negative

- Test Type: in vitro micronucleus test
  Result: negative

**Genotoxicity in vivo:**
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  Species: Rat
  Application Route: Oral
  Result: negative

- Test Type: Mammalian spermatogonial chromosome aberration test (in vivo)
  Species: Hamster
  Result: negative

**Germ cell mutagenicity - Assessment:**
- Weight of evidence does not support classification as a germ cell mutagen.

**Gentamicin:**

**Genotoxicity in vitro:**
- Test Type: In vitro mammalian cell gene mutation test
  Result: negative

- Test Type: Chromosome aberration test in vitro
  Result: equivocal

**Genotoxicity in vivo:**
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  Species: Mouse
  Application Route: Intravenous injection
  Result: negative

**Mometasone:**

**Genotoxicity in vitro:**
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative

- Test Type: Chromosomal aberration
  Test system: Chinese hamster lung cells
  Result: negative

- Test Type: Chromosomal aberration
  Test system: Chinese hamster ovary cells
Result: positive
Test Type: Mouse Lymphoma
Result: negative

Genotoxicity in vivo
Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Test Type: Chromosomal aberration
Species: Rat
Cell type: Bone marrow
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat
Cell type: Liver cells
Result: negative

Germ cell mutagenicity - Assessment
Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity
Not classified based on available information.

Components:

White mineral oil (petroleum):
Species: Rat
Application Route: Ingestion
Exposure time: 24 Months
Result: negative

clotrimazole:
Species: Rat
Application Route: Oral
Exposure time: 78 weeks
Result: negative

Gentamicin:
Carcinogenicity - Assessment: No data available

Mometasone:
Species: Rat
Application Route: Inhalation
Exposure time: 2 Years
Dose: 0.067 mg/kg body weight
Result: negative
Species: Mouse
Application Route: Inhalation
Exposure time: 19 Months
Dose: 0.160 mg/kg body weight
Result: negative

Reproductive toxicity
May damage the unborn child.

Components:

White mineral oil (petroleum):
Effects on fertility: Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Skin contact
Result: negative

Effects on foetal development: Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative

clotrimazole:
Effects on fertility: Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Oral
Fertility: LOAEL: 50 mg/kg body weight
Result: Effects on fertility

Effects on foetal development: Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 100 mg/kg body weight
Result: Embryo-foetal toxicity, No teratogenic effects

Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 50 mg/kg body weight
Result: Embryo-foetal toxicity, No teratogenic effects

Test Type: Embryo-foetal development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 200 mg/kg body weight
Result: No effects on foetal development

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 180 mg/kg body weight
Result: No effects on foetal development

Reproductive toxicity - As:
Some evidence of adverse effects on sexual function and
**SAFETY DATA SHEET**

**Mometasone / Clotrimazole / Gentamicin Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue: 23.03.2020</th>
<th>Date of first issue: 14.12.2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.8</td>
<td>10.10.2020</td>
<td>412809-00015</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Gentamicin:**

<table>
<thead>
<tr>
<th>Effects on fertility</th>
<th>Test Type: Two-generation reproduction toxicity study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Species: Rat</td>
</tr>
<tr>
<td></td>
<td>Fertility: NOAEL: 20 mg/kg body weight</td>
</tr>
<tr>
<td></td>
<td>Result: No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

**Effects on foetal development**

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rabbit</td>
</tr>
<tr>
<td>Developmental Toxicity: NOAEL: 3.6 mg/kg body weight</td>
</tr>
<tr>
<td>Result: No embryo-foetal toxicity</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
</tr>
<tr>
<td>Application Route: Intraperitoneal</td>
</tr>
<tr>
<td>Developmental Toxicity: LOAEL: 75 mg/kg body weight</td>
</tr>
<tr>
<td>Result: Embryo-foetal toxicity</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Mouse</td>
</tr>
<tr>
<td>Application Route: Intraperitoneal</td>
</tr>
<tr>
<td>Developmental Toxicity: LOAEL: 10 mg/kg body weight</td>
</tr>
<tr>
<td>Result: foetal mortality, No malformations were observed.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
</tr>
<tr>
<td>Application Route: Intraperitoneal</td>
</tr>
<tr>
<td>Developmental Toxicity: LOAEL: 50 mg/kg body weight</td>
</tr>
<tr>
<td>Result: foetal mortality, No malformations were observed.</td>
</tr>
</tbody>
</table>

**Mometasone:**

**Reproductive toxicity - Assessment:**

Positive evidence of adverse effects on development from human epidemiological studies.

<table>
<thead>
<tr>
<th>Effects on fertility</th>
<th>Test Type: Fertility</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Species: Rat</td>
</tr>
<tr>
<td></td>
<td>Application Route: Subcutaneous</td>
</tr>
<tr>
<td></td>
<td>Fertility: NOAEL: 0.015 mg/kg body weight</td>
</tr>
<tr>
<td></td>
<td>Symptoms: Reduced embryonic survival, Reduced foetal weight</td>
</tr>
<tr>
<td></td>
<td>Result: No effects on fertility, Effect on reproduction capacity</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Effects on foetal development</th>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Species: Mouse</td>
</tr>
<tr>
<td></td>
<td>Application Route: Subcutaneous</td>
</tr>
<tr>
<td></td>
<td>Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight</td>
</tr>
<tr>
<td></td>
<td>Result: Embryotoxic effects., Teratogenicity and developmental toxicity</td>
</tr>
</tbody>
</table>
Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Dermal  
Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight  
Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Dermal  
Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight  
Result: Embryo-foetal toxicity, Malformations were observed.

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Subcutaneous  
Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight  
Result: Effects on newborn

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight  
Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

**STOT - single exposure**
Not classified based on available information.

**Components:**

**Mometasone:**
Remarks : Based on available data, the classification criteria are not met.

**STOT - repeated exposure**
Not classified based on available information.

**Components:**

**clotrimazole:**
Target Organs : Liver, Kidney, Adrenal gland  
Assessment : May cause damage to organs through prolonged or repeated exposure.

**Gentamicin:**
Target Organs : Kidney, inner ear  
Assessment : Causes damage to organs through prolonged or repeated exposure.
Mometasone:
Exposure routes: inhalation (dust/mist/fume)
Target Organs: Immune system, Liver, Kidney, Skin
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

White mineral oil (petroleum):
Species: Rat
LOAEL: 160 mg/kg
Application Route: Ingestion
Exposure time: 90 Days

Species: Rat
LOAEL: >= 1 mg/l
Application Route: inhalation (dust/mist/fume)
Exposure time: 4 Weeks
Method: OECD Test Guideline 412

Clotrimazole:
Species: Rabbit
LOAEL: 5 - 40 mg/kg
Application Route: Skin contact
Exposure time: 3 Weeks
Target Organs: Skin
Symptoms: Oedema, Fissuring, Necrosis, Redness

Species: Rat
LOAEL: 10 mg/kg
Application Route: Oral
Exposure time: 18 Months
Target Organs: Liver, Kidney, Adrenal gland

Species: Dog
LOAEL: 25 mg/kg
Application Route: Oral
Exposure time: 6 - 12 Months
Target Organs: Adrenal gland
Symptoms: Salivation, Lachrymation, Vomiting

Gentamicin:
Species: Dog
LOAEL: 3 mg/kg
Application Route: Intramuscular
Exposure time: 12 Months
Target Organs: Kidney
Symptoms: Vomiting, Salivation

Species: Monkey
<table>
<thead>
<tr>
<th>LOAEL</th>
<th>50 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>3 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Kidney, inner ear</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>6 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>Exposure time</td>
<td>3 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Blood, Kidney, inner ear, Liver</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>5 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>Exposure time</td>
<td>52 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Kidney, Blood</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>12.5 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>50 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>Exposure time</td>
<td>13 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Kidney</td>
</tr>
</tbody>
</table>

**Mometasone:**

*Species*: Rat

<table>
<thead>
<tr>
<th>NOAEL</th>
<th>0.005 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>0.3 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>30 d</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Lymph nodes, Liver, Adrenal gland, Skin, thymus gland</td>
</tr>
</tbody>
</table>

*Species*: Dog

<table>
<thead>
<tr>
<th>NOAEL</th>
<th>0.5 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>30 d</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Lymph nodes, Liver, Adrenal gland, Skin, thymus gland</td>
</tr>
</tbody>
</table>

*Species*: Rat

<table>
<thead>
<tr>
<th>NOAEL</th>
<th>0.00013 mg/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>inhalation (dust/mist/fume)</td>
</tr>
<tr>
<td>Exposure time</td>
<td>90 d</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland</td>
</tr>
</tbody>
</table>

*Species*: Dog

<table>
<thead>
<tr>
<th>NOAEL</th>
<th>0.0005 mg/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>inhalation (dust/mist/fume)</td>
</tr>
<tr>
<td>Exposure time</td>
<td>90 d</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver</td>
</tr>
</tbody>
</table>
Aspiration toxicity
Not classified based on available information.

Components:
Mometasone: Not applicable

Experience with human exposure

Components:
clotrimazole:
Skin contact: Symptoms: Rash, Itching, Blistering, Oedema, Redness
Ingestion: Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhoea

Gentamicin:
Ingestion: Target Organs: Kidney
          Target Organs: inner ear
          Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal deafness

Mometasone:
Inhalation: Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion
Skin contact: Symptoms: Dermatitis, Itching

Further information

Components:
Mometasone:
Remarks: Dermal absorption possible

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:
White mineral oil (petroleum):
Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants: NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity): NOEC (Oncorhynchus mykiss (rainbow trout)): 1,000 mg/l
Exposure time: 28 d

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC (Daphnia magna (Water flea)): 1,000 mg/l
Exposure time: 21 d

**clotrimazole:**

Toxicity to fish: LC50 (Brachydanio rerio (zebrafish)): > 0.29 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 0.02 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants: EC50 (Desmodesmus subspicatus (green algae)): 0.268 mg/l
Exposure time: 72 h
NOEC (Desmodesmus subspicatus (green algae)): 0.017 mg/l
Exposure time: 72 h

Toxicity to fish (Chronic toxicity): NOEC (Oncorhynchus mykiss (rainbow trout)): 0.025 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC (Daphnia magna (Water flea)): 0.01 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms: EC50: > 10,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

**Gentamicin:**

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 86 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

LC50 (Americamysis): 30 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): 10 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 1.5 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
EC50 (Anabaena flos-aquae (cyanobacterium)): 4.7 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 1.6 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms:
EC50: 288.7 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

**Mometasone:**

Toxicity to fish:
LC50 (Menidia beryllina (Silverside)): 0.11 mg/l
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates:
EC50 (Daphnia magna (Water flea)): > 5 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility

EC50 (Americamysis): > 5 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035
Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants:
EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity):
NOEC (Pimephales promelas (fathead minnow)): 0.00014 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
NOEC (Daphnia magna (Water flea)): 0.34 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms:
EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility

NOEC: 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility

Persistence and degradability

Components:

White mineral oil (petroleum):
Biodegradability: Result: Not readily biodegradable.
Biodegradation: 31 %
Exposure time: 28 d

clotrimazole:
Stability in water: Hydrolysis: 50 % (242 d)

Gentamicin:
Biodegradability: Result: rapidly degradable
Biodegradation: 100 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Mometasone:
Biodegradability: Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Stability in water: Hydrolysis: 50 % (12 d)
Method: OECD Test Guideline 111

Bioaccumulative potential

Components:

Gentamicin:
Partition coefficient: n-octanol/water: log Pow: < -2

Mometasone:
Bioaccumulation: Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 107.1
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water: log Pow: 4.68
Mobility in soil

Components:

Mometasone:
Distribution among environmental compartments: log Koc: 4.02

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
UN number: UN 3082
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (clotrimazole, Gentamicin)
Class: 9
Packing group: III
Labels: 9

IATA-DGR
UN/ID No.: UN 3082
Proper shipping name: Environmentally hazardous substance, liquid, n.o.s. (clotrimazole, Gentamicin)
Class: 9
Packing group: III
Labels: Miscellaneous
Packing instruction (cargo aircraft): 964
Packing instruction (passenger aircraft): 964
Environmentally hazardous: yes

IMDG-Code
UN number: UN 3082
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (clotrimazole, Gentamicin)
Class: 9
Packing group: III
Labels: 9
EmS Code: F-A, S-F
SAFETY DATA SHEET

Mometasone / Clotrimazole / Gentamicin Formulation

Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations

ADG
UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (clotrimazole, Gentamicin)
Class : 9
Packing group : III
Labels : 9
Hazchem Code : •3Z

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Prohibition/Licensing Requirements : There is no applicable prohibition, authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regulations.

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information
Revision Date : 10.10.2020
Date format : dd.mm.yyyy
SAFETY DATA SHEET

Mometasone / Clotrimazole / Gentamicin Formulation

Full text of other abbreviations

ACGIH: USA. ACGIH Threshold Limit Values (TLV)
AU OEL: Australia. Workplace Exposure Standards for Airborne Contaminants.

ACGIH / TWA: 8-hour, time-weighted average
AU OEL / TWA: Exposure standard - time weighted average

All abbreviations are defined in the text following the table above.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN